Clinical trials: Poliovirus Vaccine, Oral
Polio
Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3
Globally, polio cases have decreased by over 99% since 1988. However, wild poliovirus cases continue in Pakistan. Conflict and lack of access to children due to on-going insecurity in tribal areas present special challenges in…
- Trial name
- SIAD (NCT01586572)
- Testing
- mOPV1, bOPV 1,3
- Where
- 2 sites in Pakistan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Poliomyelitis
Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV
With the progress of the eradication of polio, bivalent oral attenuated live poliomyelitis vaccine against type 1 and 3 (bOPV) and inactivated poliomyelitis vaccine made by Sabin strain (sIPV) are required to use in the "Strategy…
- Trial name
- NCT03614702
- Testing
- 1-dose cIPV + 2-doses bOPV (Candy), 1-dose sIPV + 2-doses bOPV (Candy), 2-doses cIPV + 1-dose bOPV (Candy)
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Poliomyelitis
Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
The purpose of this study is to evaluate the safety and tolerability of co-administration of nOPV1 + nOPV2 in infants, relative to those receiving monovalent nOPV vaccines alone and whether two and/or three doses of…
- Trial name
- SCOPE (NCT06895486)
- Testing
- Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 2 (nOPV2)
- Where
- 3 sites in Panama
- Volunteers
- 675 people, healthy volunteers welcome
- Sponsor
- PATH
Oral Polio Vaccine
Use of mOPV1 in Routine Immunization in Pakistan.
Pakistan has uninterrupted circulation of polioviruses and this may threaten the entire global community. Bivalent OPV (bOPV), which protects against types 1 and 3, is used for routine immunization.
- Trial name
- mOPV1 (NCT04504539)
- Testing
- mOPV, bOPV, Full dose IPV
- Where
- Pakistan
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Poliomyelitis
Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine
Trail To Evaluate the Immunity Duration of healthy children who already took part in " The safety and immunogenicity by different sequential schedules of bOPV and bOPV in dragee candy with sIPV, a randomized, double blind, single…
- Trial name
- NCT03821441
- Testing
- bOPV(Candy), bOPV(Liquid)
- Where
- China
- Volunteers
- 1,165 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Adverse Event Following Immunisation
A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children
Sabin 2 will be withdrawn from routine use globally from April 2016 as per the SAGE recommendations at the time of writing this protocol.
- Trial name
- M2-ABMG (NCT02521974)
- Testing
- SABIN monovalent OPV2
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Poliomyelitis
Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
The purpose of this clinical trial is to assess the safety and tolerability (primary objective), immunogenicity (primary and secondary objectives), fecal shedding of vaccine viruses (secondary objective) and the potential for…
- Trial name
- NCT05654467
- Testing
- Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3), Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)
- Where
- 3 sites in Panama
- Volunteers
- 1,532 people, healthy volunteers welcome
- Sponsor
- PATH
Poliomyelitis
Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
The purpose of this clinical trial is to assess the safety and tolerability (primary objective), immunogenicity (primary and secondary objectives), fecal shedding of vaccine viruses (secondary objective) and the potential for…
- Trial name
- NCT05644184
- Testing
- Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1), Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)
- Where
- Bangladesh
- Volunteers
- 2,232 people, healthy volunteers welcome
- Sponsor
- PATH
Immunity to Oral Rotavirus Vaccine, Immunity to Oral Polio Vaccine
Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines
Background: Strategies are needed to improve oral rotavirus vaccine (RV), which provides suboptimal protection in developing countries.
- Conditions
- Immunity to Oral Rotavirus Vaccine, Immunity to Oral Polio Vaccine, Shedding of Oral Rotavirus Vaccine
- Trial name
- NCT01616693
- Testing
- Probiotic, Zinc, Rotavirus vaccine
- Where
- India
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- PATH
Coronavirus Infections, Vaccine
Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Observational program, double-blind, placebo-controlled to study the preventive efficacy of the BiVac polio (Oral polio vaccine, divalent, live attenuated of types 1 and 3 vaccine against the incidence of acute respiratory…
- Conditions
- Coronavirus Infections, Vaccine, Polio
- Trial name
- NCT05083039
- Where
- Russia
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Poliomyelitis
Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine
Type 2 component of oral poliovirus vaccine is slated for global withdrawal through a switch from trivalent oral poliovirus vaccine (tOPV) to bivalent oral poliovirus vaccine (bOPV) for preventing paralytic polio caused by…
- Trial name
- TTbOPV (NCT02785705)
- Testing
- poliovirus vaccine
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
Poliomyelitis
Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults
This first-in-human (FIH) phase 1 study is designed to evaluate in contained conditions the safety, immunogenicity, shedding, and genetic stability of two novel oral polio vaccine type 2 (nOPV2) vaccine candidates in IPV-primed…
- Trial name
- nOPV2M4a (NCT03430349)
- Testing
- Novel OPV2 candidate 1, Novel OPV2 candidate 2
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pierre Van Damme
Poliomyelitis
Immunogenicity nOPV2 With and Without bOPV
This is an open-label randomized clinical trial that will compare immune responses among infants who receive either novel monovalent oral poliovirus vaccine type 2 (nOPV2) alone, bivalent oral poliovirus vaccine (bOPV) alone, or…
- Trial name
- NCT04579510
- Testing
- Novel monovalent oral poliovirus vaccine type 2 (nOPV2), Bivalent oral poliovirus vaccine (bOPV)
- Where
- Bangladesh
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Poliomyelitis
A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates
This study is designed to evaluate the safety and immunogenicity of two novel type 2 oral poliovirus vaccine (nOPV2) candidates (nOPV2 candidate 1 and nOPV2 candidate 2) in adults.
- Trial name
- NCT04544787
- Testing
- Novel OPV2 candidate 1, Novel OPV2 candidate 2
- Where
- 2 sites in Belgium
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Pierre Van Damme
Polio, Measles
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.
- Conditions
- Polio, Measles, Rubella, Mumps
- Trial name
- NCT07338851
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Poliomyelitis
Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine
The purpose of this study will be to evaluate whether a bivalent oral polio vaccine (bOPV) manufactured by Beijing Bio-Institute Biological Products Co., Ltd (BBIBP) has a similar immunogenicity profile to a WHO prequalified bOPV.
- Trial name
- NCT02434770
- Testing
- BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1, BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2, BioFarma Bivalent Oral Poliomyelitis Vaccine
- Where
- 2 sites in Kenya
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- PATH
Poliomyelitis
Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study
This is an open-label phase IV randomized clinical trial that will assess intestinal and humoral immunity among infants who receive a combination of monovalent oral poliovirus vaccine type 1 and fractional dose of inactivated…
- Trial name
- mOPV1 (NCT03722004)
- Testing
- mOPV1, bOPV, fIPV
- Where
- Bangladesh
- Volunteers
- 1,256 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Immune Response to Oral Polio Vaccine
A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals
Bilthoven Biologicals has developed a new bivalent oral polio vaccine (bOPV) containing World Health Organization (WHO) approved Sabin strains of poliovirus type 1 and type 3.
- Trial name
- NCT02766816
- Testing
- Part 1 study - BBio bOPV, Part 2 study - BBio bOPV Lot 1, Part 2 study - BBio bOPV Lot 2
- Where
- Bangladesh
- Volunteers
- 1,120 people, healthy volunteers welcome
- Sponsor
- Bilthoven Biologicals
Poliomyelitis
Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines
The main objectives of this study are to : evaluate the safety and tolerability of trivalent novel oral poliovirus vaccines (tnOPV) in healthy adults, young children, and neonates, relative to those receiving control vaccines…
- Trial name
- NCT06137664
- Testing
- Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2), Novel oral poliomyelitis vaccine type 3 (nOPV3)
- Where
- 2 sites in Bangladesh
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- PATH
Vaccine Reaction
Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine
Concomitant administration of multiple vaccines, including live attenuated immunizations, is safe and effective. Some restrictions apply for live vaccines; administering a live-virus vaccine within 4 weeks after administration of…
- Trial name
- NCT03581734
- Testing
- Oral Polio Vaccine, Oral Cholera Vaccine
- Where
- Bangladesh
- Volunteers
- 579 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh